Work

Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients

Year: 2020

Type: article

Abstract: Clinical Practice Points•Clonal plasma cell neoplasm in solid organ transplant recipients can manifest in the form of AL amyloidosis or post-transplant lymphoproliferative disorder extraosceous plasmacytoma type.•The typical treatment in clinical practice includes multiple myeloma type anti-plasma cell therapy, but there is no consensus on how to best treat this rare group of disorders.•In our series (n = 5), all patients received anti-CD38 monoclonal antibody treatment with daratumumab in combination with other agents as salvage therapy with variable clinical response.•Daratumumab-based therapy was safe and well-tolerated but was associated with increased infectious complications and did not prevent progressive kidney damage, despite achieving significant anti-plasma cell response. •Clonal plasma cell neoplasm in solid organ transplant recipients can manifest in the form of AL amyloidosis or post-transplant lymphoproliferative disorder extraosceous plasmacytoma type.•The typical treatment in clinical practice includes multiple myeloma type anti-plasma cell therapy, but there is no consensus on how to best treat this rare group of disorders.•In our series (n = 5), all patients received anti-CD38 monoclonal antibody treatment with daratumumab in combination with other agents as salvage therapy with variable clinical response.•Daratumumab-based therapy was safe and well-tolerated but was associated with increased infectious complications and did not prevent progressive kidney damage, despite achieving significant anti-plasma cell response.

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2019.12.022